A New Role for Lateral Flow in Cancer Diagnosis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A New Role for Lateral Flow in Cancer Diagnosis

  • November 19, 2026

  • 3 min

Share

  • 1

    Researchers developed a quantitative colorimetric lateral flow immunoassay to measure soluble AXL (sAXL) in plasma as a potential aid to pancreatic ductal adenocarcinoma diagnosis.

  • 2

    The assay uses capture and biotinylated detection antibodies, with anti-biotin gold nanoparticles generating a visible signal.

  • 3

    In a cohort of 20 patients with pancreatic ductal adenocarcinoma and 20 healthy controls, the assay detected higher sAXL concentrations and statistically differentiated the groups.

  • 4

    The study was an early clinical evaluation and did not assess whether the assay distinguishes pancreatic cancer from chronic pancreatitis or other relevant diseases.

  • 5

    The findings do not establish the assay for screening or as a replacement for imaging, histopathology, cytology, or laboratory ELISA; larger independent studies are needed.

Original Source(s)

Related Content